US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
MADRID (Reuters) -A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on Friday.
Based on its findings, the Federal District Court for the Southern District of New York rejected a request filed by Gotham City to dismiss the lawsuit, Grifols said.
In January 2024, Gotham, which had previously shorted Grifols shares, released a report accusing the company of overstating earnings and understating debt. Grifols denied the allegations but lost around a third of its market value following the report.
Shorting involves borrowing shares in order to sell them, with the hope of buying them back more cheaply to make a profit.
According to Grifols, the court also found that Grifols adequately argued that Gotham City's report contained false statements, such as that the company had failed to disclose a $95 million loan to Scranton Enterprises.
Gotham City did not immediately respond to a request for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
24 minutes ago
- Bloomberg
Lex Greensill Set to Testify in $440 Million Credit Suisse UK Trial
Lex Greensill will testify in court for the first time since the high-profile collapse of his trade finance firm, as a $440 million Credit Suisse lawsuit against SoftBank Group Corp. gets underway. Evidence from the embattled financier will be the centerpiece of a month long London trial that starts on Thursday over investor losses in a failed startup. Credit Suisse is seeking damages from SoftBank alleging that a series of transactions with Greensill deprived its investors of $440 million in funds.
News24
24 minutes ago
- News24
TotalEnergies on trial in landmark greenwashing case in France
Oil and gas giant TotalEnergies goes on trial in Paris over allegations of misleading climate claims. Three environmental groups lodged the case in March 2022 accusing TotalEnergies of 'misleading commercial practices.' TotalEnergies maintains it has not engaged in misleading commercial practices. For climate change news and analysis, go to News24 Climate Future. French oil and gas giant TotalEnergies goes on trial in Paris on Thursday over allegations of misleading climate claims, an unprecedented "greenwashing" case against a fossil fuel firm in France. The civil case stems from a March 2022 lawsuit by three environmental groups accusing the French energy giant of "misleading commercial practices" for saying it could reach carbon neutrality while continuing oil and gas production. Starting in May 2021, TotalEnergies advertised its goal of "carbon neutrality by 2050" and touted gas as "the fossil fuel with the lowest greenhouse gas emissions". At the time, the company had also changed its name from Total to TotalEnergies to emphasise its investments in low-carbon energy, such as electricity. The plaintiffs have logged around 40 "false advertisements" in their lawsuit. The ads "don't sincerely reflect the reality of TotalEnergies' operations", Apolline Cagnat, a legal counsel at Greenpeace, told AFP. Cagnat said the NGOs want the court to send a "strong signal" to fossil fuel companies by ordering "an immediate stop, under penalty, of the misleading commercial practices". READ | Air pollution linked to 42 000 SA deaths in 2023, report urges renewable energy shift TotalEnergies disputes the charges, insisting the messages are part of its institutional communication, regulated by financial authorities - not consumer law. It argues no consumer organisation is party to the case, and that the NGOs are misusing consumer protection rules to challenge its corporate strategy. Environmental groups in recent years have turned to the courts to establish case law on companies misleading consumers by appearing more eco-friendly than they are. In Europe, courts ruled against Dutch airline KLM in 2024 and Germany's Lufthansa in March over misleading consumers about their efforts to reduce the environmental impact of flying. In Spain, utility Iberdrola failed to secure a conviction against Spanish oil and gas company Repsol over similar allegations of "false" environmental claims. A greenwashing case against Australian oil and gas producer Santos, challenging its claim to be a "clean fuels" company, has been ongoing since 2021. Based on a European Union directive targeting unfair commercial practices, the TotalEnergies lawsuit is the first time a French court has heard such a case against a fossil fuel company. The NGOs said the Paris court will rule, for the first time in the world, on the legality of ads presenting gas as essential to the energy transition. Climate experts say methane leaks from the gas industry have a powerful warming effect on the atmosphere. TotalEnergies maintains it has not engaged in misleading commercial practices. The company says it plans to show that its messages "about its name change, strategy and role in the energy transition are reliable and based on objective, verifiable data".
Medscape
29 minutes ago
- Medscape
Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC
The latest results from the BREAKWATER trial have confirmed encorafenib plus cetuximab with chemotherapy as the new first-line standard of care for BRAF V600E-mutant metastatic colorectal cancer (CRC), according to research presented at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. At the interim analysis, encorafenib plus cetuximab with mFOLFOX6 chemotherapy doubled median overall survival compared with the current standard of care — investigators' choice of chemotherapy with or without bevacizumab. In addition, at a median follow-up of 16.8 months, the new treatment regimen led to a significant improvement in median progression-free survival of almost 6 months. This survival finding is 'unprecedented' and 'practice changing' for these patients who historically have a poor prognosis, said lead investigator and presenter Elena Élez, MD, PhD, a gastrointestinal medical oncologist at the Vall d'Hebron University Hospital in Barcelona, Italy. The study was published in The New England Journal of Medicine to coincide with Élez's presentation. BRAF mutations, which occur in up to 12% of patients with metastatic CRC, are associated with poor outcomes. In December 2024, the US Food and Drug Administration (FDA) granted accelerated approval for the BRAF inhibitor encorafenib alongside cetuximab and mFOLFOX6 for patients with metastatic CRC and a BRAF V600E mutation. This approval was based on earlier results from BREAKWATER that showed a 21% higher objective response rate and a longer duration of response with this regimen. The accelerated approval means that this regimen has already been making its way into the clinic, but 'we were all waiting for this [latest] data,' Pamela Kunz, MD, chief of Gastrointestinal Medical Oncology at Yale University in New Haven, Connecticut, told Medscape Medical News . The doubling of overall survival 'is a big deal,' she said. In the trial, patients were randomly assigned to receive either first-line encorafenib plus cetuximab with mFOLFOX6 (n = 236) or to a control group — physician's choice of either mFOLFOX6, FOLFOXIRI, or CAPOX chemotherapy (n = 243). Most patients in the control arm also received the tumor angiogenesis inhibitor bevacizumab. The broad options in the control arm speak to how heterogeneous treatment has been for BRAF V600E-mutant metastatic CRC, said study discussant Andrea Sartore-Bianchi, MD, a medical oncologist at the University of Milan, Milan, Italy. Patients in the trial had received no prior systemic therapy for metastatic disease. Investigators excluded patients with high levels of microsatellite instability because they are candidates for immunotherapy. At a median follow-up of 16.8 months, median progression-free survival was 12.8 months for the encorafenib group compared with 7.1 months for the control group (hazard ratio [HR], 0.53; P < .0001). At a median follow-up of 22 months, overall survival was 30 months in the encorafenib group compared with 15 months in the control group (HR, 0.49; P < .0001). The benefits of the combination were held up in high-risk subgroups, including in patients with liver metastases and those with metastases in three or more organs. With the use of more agents and a longer duration of treatment due to improved efficacy, there was an expected increase in toxicity with the new regimen. The rate of treatment-related grade 3/4 adverse events was 76.3% with encorafenib vs 58.5% with the control regimen. Patients receiving encorafenib also had higher rates of anemia, arthralgia, rash, and pyrexia, but there was no substantial increase in treatment discontinuation. BREAKWATER also included an encorafenib plus cetuximab arm without chemotherapy, but enrollment was stopped early at 158 patients due to possible futility. Still, these patients had as good or numerically better outcomes than the control group, which means the drug combination alone is a valid option for those unable to tolerate chemotherapy, said Élez. 'The results are striking,' said Sartore-Bianchi in his discussion. 'Now that we have the big picture' from BREAKWATER, the combination should be considered the first-line standard of care. Mark A. Lewis, MD, a gastrointestinal medical oncologist at Intermountain Healthcare in Murray, Utah, explained that what usually happens in metastatic CRC is that people are treated with chemotherapy for a bit before oncologists notice the tumor is behaving more aggressively than expected and order a BRAF test. This delay is now 'completely unacceptable,' he told Medscape Medical News . The takeaway from BREAKWATER is that testing must come sooner. To help with BRAF testing, the FDA approved the Qiagen therascreen BRAF V600E RGQ polymerase chain reaction kit. 'As soon as you know patients are BRAF -mutated, you need to play your entire hand' because it will double survival,' said Lewis. 'This absolutely validates a biomarker-informed approach to colon cancer,' similar to what we have in breast cancer. BREAKWATER was funded primarily by Pfizer, maker of encorafenib, with support from Eli Lilly and Merck, who jointly market cetuximab. Élez reported numerous ties to the companies, including research grants, travel funding, honoraria, and/or consultant work. Lewis, Kunz, and Sartore-Bianchi had no relationships with the firms.
